Flibanserin powder, sold under the trade name Addyi. Flibanserin powder is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three. The certainty of the estimate is low.
02 Contact Us
03 Flibanserin Powder (167933-07-5) video
04 Flibanserin Powder (167933-07-5) Base Information
|Molecular Weight||390.4 g/mol|
|Half Life||≈11 hours|
|Solubility||Water Solubility 0.178 mg/mL|
|Storage Condition||Store in a sealed airtight container, keep the air out, protected from heat, light and humidity.|
|Application||Use for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD)|
05 Flibanserin Powder (167933-07-5) General Description
Flibanserin powder, people also search for Addyi, it is a new non-hormonal prescription medication for hypoactive sexual desire disorder (HSDD) in women. Flibanserin powder is the first medicine ever specifically approved to treat loss of sexual desire in either men or women.
It’s also potentially important for sexual science — since FDA approval of flibanserin is likely to lead to much more research on the neurochemistry of desire.
06 Flibanserin Powder (167933-07-5) History
Flibanserin powder is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals.
07 Flibanserin Powder (167933-07-5) Mechanism Of Action
Flibanserin’s mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
08 Flibanserin Powder (167933-07-5) Application
Flibanserin powder is used to treat women who have not gone through menopause who have low sexual desire and are concerned about it.
Flibanserin powder should not be used to treat low sexual desire caused by: a medical or mental/mood disorder, problems in the relationship, or the effects of other drugs. This medication should not be used by women who have gone through menopause, or by men. Flibanserin powder is not used to enhance sexual performance.
09 Flibanserin Powder (167933-07-5) More research
People may ask “Is Flibanserin safe?” “What are Flibanserin side effects?”
The clinical trials data presented to the FDA on flibanserin included results from over 11,000 patients — one of the largest data-sets ever presented in the FDA’s history. The safety of this medication has been evaluated more stringently than that of most new drugs approved by the FDA. That being said, there is still much that is unknown about flibanserin — as with any other recently-approved medication. Rare but serious Flibanserin side effects are sometimes only discovered after a drug has been in general use for months or years.
The two Flibanserin side effects that the FDA looked at most carefully before approving flibanserin were sedation, and dizziness or fainting due to a drop in blood pressure.
10 Flibanserin Powder (167933-07-5) Document Download
11 Flibanserin Powder (167933-07-5) Reference
 “Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee” (PDF). June 4, 2015. Retrieved 5 June 2015.
 Invernizzi, Roberto William; Sacchetti, Giuseppina; Parini, Stefania; Acconcia, Sabrina; Samanin, Rosario (2003). “Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1Areceptors”. British Journal of Pharmacology. 139 (7): 1281–1288. doi:10.1038/sj.bjp.0705341. ISSN 0007-1188. PMC 1573953. PMID 12890707.
 “Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women”. 27 June 2013.
 Pollack, Andrew (2015-06-04). “‘Viagra for Women’ Is Backed by an F.D.A. Panel”. The New York Times.
12 PRECAUTION AND DISCLAIMER:
PRECAUTION AND DISCLAIMER:
This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.
- 01. Overview
- 02. Contact Us
- 03. Flibanserin Powder (167933-07-5) video
- 04. Flibanserin Powder (167933-07-5) Base Information
- 05. Flibanserin Powder (167933-07-5) General Description
- 06. Flibanserin Powder (167933-07-5) History
- 07. Flibanserin Powder (167933-07-5) Mechanism Of Action
- 08. Flibanserin Powder (167933-07-5) Application
- 09. Flibanserin Powder (167933-07-5) More research
- 10. Flibanserin Powder (167933-07-5) Document Download
- 11. Flibanserin Powder (167933-07-5) Reference
- 12. PRECAUTION AND DISCLAIMER: